Close Menu

People in the News

Feb 08, 2021

Sema4: Isaac Ro

Isaac Ro has been appointed as CFO of Sema4. Previously, he was CFO of Thrive Earlier Detection, which was recently acquired by Exact Sciences. Prior to that, he led the US medical technology team at Goldman Sachs, where he covered life science tools, diagnostics, and medical technology. Before that, he held a similar role at SVB Leerink.

Feb 05, 2021

Interpace Biosciences: Tom Freeburg, Fred Knechtel

Interpace Biosciences has appointed Tom Freeburg as its CFO, succeeding Fred Knechtel effective Feb. 1. Freeburg previously served as chief accounting officer at the firm. Prior to Interpace, he served in senior finance roles at several other firms, including Cambridge Financial Consultants, Coach, Scholastic, and DRS Technologies.  

Feb 05, 2021

Swift Biosciences: Bruce Zhang

Swift Biosciences has appointed Bruce Zhang to its global commericial team as director of sales and marketing of Asia-Pacific (APAC). According to Zhang's Linkedin profile, he previously served as senior business developer of APAC at Covaris. Prior to Covaris, he held roles at Abcam and GenScript. 

Feb 04, 2021

Mammogen: Elizabeth Cormier-May

Mammogen has appointed Elizabeth Cormier-May as its CEO and as a member of the firm's board of directors. Cormier-May is currently cofounder, president, and CEO of Persona Health. Prior to Persona Health, she served as VP and head of commercial operations at Exosome Dx. She has also served in roles at Novartis Pharmaceuticals, Myriad Genetics, Qiagen, and Predictive Biosciences.  

Feb 03, 2021

GenapSys: Jason Myers, Hesaam Esfandyarpour

GenapSys has named Jason Myers CEO, effective Feb. 15, 2021, replacing founder Hesaam Esfandyarpour. Myers will also join the board of directors. 

Myers comes to GenapSys from Invitae, where he was president of oncology. Prior to that, he was president and CEO of ArcherDx, which he also cofounded, until Invitae acquired the company last October. He also previously held positions at Ion Torrent, and holds a doctorate molecular pharmacology from Stanford University. Myers will continue to serve on Invitae's board of directors.

Esfandyarpour, who served as CEO since 2010, will remain as GenapSys' chairman. 

Feb 03, 2021

Talis Biomedical: Melissa Gilliam

Talis Biomedical, a developer of molecular point-of-care infectious disease diagnostic tests, has appointed Melissa Gilliam to its board of directors. Gilliam is the Ellen H. Block Professor of Health Justice and vice provost of the University of Chicago. She is also a professor of obstetric and gynecology and professor of pediatrics at the university, and is the founder and director of the Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive Health. Gilliam holds a BA in English from Yale University, an MA in philosophy and politics from Oxford University, an MD from Harvard Medical School, and an MPH in epidemiology and biostatistics from the University of Illinois at Chicago. She completed her residency in obstetrics and gynecology at Northwestern University.

Feb 03, 2021

Glympse Bio: Jessica Atkinson

Glympse Bio, a Cambridge, Massachusetts-based company developing bioengineered, tunable biosensors to detect disease and gauge treatment response, has named Jessica Atkinson as senior vice president of business development. Atkinson most recently served as VP of biopharma business development at Foundation Medicine, and prior to that was senior director of corporate business development. Prior to Foundation Medicine, she held a business development role at Asuragen.

Feb 02, 2021

Rheonix: Roy Proujansky, Irving Nachamkin

Rheonix has named Roy Proujansky and Irving Nachamkin to its board of directors.

Proujansky has served for more than 30 years in physician, hospital, and health system leadership positions. At Nemours Children's Hospital, his roles included chief executive for the physician practice, chief operating officer for the Nemours Children's Health System, and chief executive for the DuPont Hospital for Children and Delaware Valley Operations. He is currently a professor of pediatrics at the Sidney Kimmel College of Medicine at Thomas Jefferson University.

Nachamkin is professor emeritus of pathology and laboratory medicine and the immediate past director of the division of laboratory medicine and associate director of the clinical microbiology laboratory at the Perelman School of Medicine and Hospital of the University of Pennsylvania. He is an expert in clinical microbiology with a focus on laboratory diagnostics, molecular diagnostics in infectious diseases, and laboratory management, and is a fellow of the American Academy of Microbiology, Infectious Diseases Society of America, and College of Physicians of Philadelphia.

Feb 02, 2021

VolitionRx: Terig Hughes, Gaetan Michel, Gael Forterre, Mark Eccleston

VolitionRx has appointed Terig Hughes its CFO. Additionally, Gaetan Michel was appointed the company's chief operating officer, Gael Forterre was appointed its chief commercial officer, and Mark Eccleston was appointed its chief technology officer.

Hughes has more than 25 years of accounting, finance, and business management experience and was previously at AUM Biosciences as its CFO. Prior to that, he held senior leadership positions at Elsevier. Forterre was previously CEO of communications technology firm Ucroo. Michel has been at Voliton for almost seven years and previously was COO of Belgian Volition, where he is currently its CEO. Eccleson was a founding scientist at Volition.

Jan 28, 2021

Biofidelity: Wendy Levin

Biofidelity has appointed Wendy Levin as its chief medical officer. She has more than 15 years of experience in the biotechnology space, including as a VP and CMO at two publicly traded companies where she led clinical development and medical affairs, and supported business development.

Jan 27, 2021

Epigenomics: Jorge Garces

Jorge Garces will resign as president and CSO of Epigenomics, effective Jan. 31. He will remain a company advisor through the end of 2021.

Jan 27, 2021

Becton Dickinson: Tom Polen, Vincent Forlenza

Becton Dickinson has named CEO Tom Polen as chairman of the board of directors, effective April 28, 2021. Polen will succeed Vincent Forlenza, who will retire from BD at that time.

Jan 27, 2021

Adaptive Biotechnologies: Mark Adams, Nancy Hill

Adaptive Biotechnologies has appointed Mark Adams as chief operating officer effective Jan. 25, 2021. Adams, 53, joined Adaptive in April 2020 as chief technical officer.  

Adams holds a PhD in cell biology from Baylor College of Medicine and completed his postdoc in computational biology at Boston University.

On Jan. 21, 2021, Adaptive and Nancy Hill, the firm's executive VP of operations and program management, agreed that her tenure will be terminated, effective March 2, 2021. Hill's termination is not the result of any material disagreement with the company regarding its operations, policies, or practices, Adaptive said in a filing with the US Securities and Exchange Commission.

Jan 26, 2021

AMP COVID Response Steering Committee: Frederick Nolte, Karen Kaul, and More

The Association for Molecular Pathology announced the creation of the AMP COVID Response Steering Committee to coordinate the organization's efforts during the pandemic. Eight people were named to the committee, including Frederick Nolte, the chair of the committee and the former chair of the AMP Infectious Diseases Subdivision, who is the professor and vice-chair for laboratory medicine at Medical University of South Carolina, and Karen Kaul, a former AMP president and a clinical professor of pathology at University of Chicago's Pritzker School of Medicine.

Other appointees are Eric Konnick, the co-chair of the AMP Professional Relations Committee and assistant professor and associate director of the Genetics and Solid Tumor Laboratory at University of Washington; Jordan Laser, the other co-chair of the AMP Professional Relations Committee and an associate professor of pathology and laboratory medicine at Hofstra; Timothy O'Leary, a former AMP president and the former chief research and development officer at the Department of Veterans Affairs; Antonia Sepulveda, AMP president and professor and chair of the George Washington School of Medicine's department of pathology; Karen Weck, the immediate past president of AMP and a professor of pathology and laboratory medicine at University of North Carolina Chapel Hill; and Donna Wolk, the chair of AMP's Infectious Diseases Subdivision and division director of molecular and microbial diagnostics and development for the Diagnostic Medicine Institute at Geisinger.

Jan 25, 2021

OncoDNA: Bernard Courtieu, Jean-Pol Detiffe, Eduardo Bravo

OncoDNA has appointed Bernard Courtieu as CEO and Jean-Pol Detiffe as chief strategic and innovation officer. Courtieu previously served as CEO of IntegraGen, which was acquired by OncoDNA last July. Prior to IntegraGen, Courtieu served as VP at Gemini Consulting.

Eduardo Bravo, who currently serves as interim CEO of OncoDNA, will remain a consultant to the firm's board. 

Jan 21, 2021

QuantuMDx: Diran Guiliguian

QuantuMDx has appointed Diran Guiliguian as chief commercial officer. He was most recently head of central lab solutions for Europe, Middle East, and Africa at Siemens Healthineers, where he led the introduction of the firm's COVID-19 testing solutions. He previously managed the diagnostics business for Southern Europe for the company.

Jan 19, 2021

Circulogene: Stephen Unger

Circulogene has appointed Stephen Unger as its CFO. Unger most recently served as a managing director of equity research at Needham & Company. He has also served as CFO of Quotient, which completed a successful initial public offering in 2014. 

Jan 19, 2021

HTG Molecular Diagnostics: Timothy Johnson, Ann Hanham

HTG Molecular Diagnostics has announced that Timothy Johnson has resigned as executive chairman and as a member of HTG's board of directors. Ann Hanham will remain as the firm's led independent director. 

Jan 19, 2021

Foundation Medicine: Cindy Perettie

Foundation Medicine, a Roche subsidiary, announced Cindy Perettie would be transitioning to Roche Diagnostics to lead the molecular lab solutions business, effective April 6. Perettie has been the CEO of Foundation Medicine since 2019 and previously served as senior VP with product strategy responsibility for the global oncology portfolio at Roche and Genentech. She also led global portfolio management for IVAX Pharmaceuticals and was the president of global development innovations at the Sarah Cannon Research Insitute in Nashville. In addition, she was previously the director of global program management at Élan Corporation in the United Kingdom. 

Brian Alexander, Foundation's chief medical officer and senior VP, will be the interim CEO for the company. 

Jan 19, 2021

LabCorp: Deborah Ann Sesok-Pizzini

Laboratory Corporation of America appointed Deborah Ann Sesok-Pizzini chief medical officer of LabCorp Diagnostics, effective Jan. 11. She replaces Dot Adcock, who is retiring in April 2021. Sesok-Pizzini was previously at The Children's Hospital of Philadelphia where she held several positions, including patient safety officer, chief of the division of transfusion medicine, and vice-chair of pathology and laboratory medicine. She also was a professor of clinical pathology and laboratory medicine at the Perelman School of Medicine at the University of Pennsylvania.

Jan 15, 2021

Broad Institute: Eric Lander, Todd Golub

Eric Lander, founding director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, has been named White House science advisor to President-elect Joseph Biden. He will specifically be nominated as director of the Office of Science and Technology Policy and serve as Presidential Science Advisor. The President-elect is designating the Presidential Science Advisor as a member of the Cabinet for the first time in history. Lander was a principal leader of the Human Genome Project, and during the Obama Administration he served as external co-chair of the President's Council of Advisors on Science and Technology.

Lander will step down from his roles at Broad, Harvard, and MIT and take an unpaid, academic leave of absence.

The Broad Institute's board has appointed Todd Golub, current chief scientific officer at the institute, as director. Golub is a founder and core member of the institute, and serves on its executive leadership team. He is also the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School. Golub joined the Dana-Farber and Harvard faculty in 1997, and served as a key scientific leader of the Whitehead Institute/MIT Center for Genome Research, the precursor organization of the Broad Institute. He has also been Howard Hughes Medical Institute investigator, and has served as chair of numerous scientific advisory boards, including St. Jude Children's Research Hospital and the National Cancer Institute's scientific advisory board.

Jan 15, 2021

Agilent Technologies: Allison Ballmer

Agilent Technologies has named Allison Ballmer as senior vice president of strategy and corporate development, reporting to President and CEO Mike McMullen.

Ballmer joined Agilent in May 2018 as vice president of business development and strategy for the company's Diagnostics and Genomics business. Prior to that, she worked for more than a decade at Roche. She is currently lead director of the board of directors at Mission Bio.

Jan 15, 2021

Exact Sciences: Andrew Slavitt

In a filing with the US Securities and Exchange Commission, Exact Sciences said that Andrew Slavitt submitted his resignation as a member of the company's board on Jan. 11 after having been been appointed by President-elect Joseph Biden as a White House Senior Advisor for COVID Response. 

Jan 14, 2021

Lunaphore Technologies: Paolo Ascierto, Jérôme Galon

Swiss life sciences company Lunaphore Technologies appointed Paolo Ascierto and Jérôme Galon, who are experts in immuno-oncology, to its new Scientific Advisory Board.

Ascierto is the director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Tumor Institute in Naples, Italy. He is a member of the Steering Committee of the Society of Melanoma Research and the board of directors of the Society of Immunotherapy of Cancer. He is also president of the Fondazione Melanoma Onlus and the Campania Society of ImmunoTherapy of Cancer.

Galon is the director of research at INSERM (the French National Institute of Health and Medical Research) and head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris. He is the cofounder of HalioDx and chairman of its scientific council.

Jan 13, 2021

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine.